Home Diagnostics appoints Joseph Capper president, CEO and director

2/24/2009

FORT LAUDERDALE, Fla. Home Diagnostics, Inc. on Monday appointed Joseph Capper as lead executive of the diabetes diagnostics companies. Capper was named president, CEO and director.

Capper succeeds J. Richard Damron, Jr., who served in the same capacity since 2001 and will be departing the company.

"On behalf of the board, I would like to thank [Damron] for his commitment and assistance during this transition period," stated George Holley, HDI chairman. "We extend our best wishes to him and appreciate the leadership he provided to Home Diagnostics during the last eight years, which includes the company's successful public offering."

"I am pleased to appoint Joe Capper to the positions of CEO and president of Home Diagnostics and welcome him to the board," Holley added. "[Capper] garnered extensive experience in the diabetes industry during his tenure at Bayer and CCS Medical, and has an understanding of our distribution channels as well as operations and supply chain management. [Capper] is the ideal leader to join our existing strong management team in order to move Home Diagnostics to the next stage of growth by maximizing our current product expansion and capitalizing on the strength of our distribution network."

"I have been familiar with Home Diagnostics as a business partner for many years and look forward to leveraging my experience in the field to help accelerate the growth and expansion of our business," Capper said. "I have great respect for the company's ability to innovate, the product portfolio and the market position they have achieved in the industry. I am extremely excited about the opportunity to join the Home Diagnostics team and look forward to capitalizing on our strong product line and market position."

Capper most recently was president and CEO of CCS Medical, a medical supply management company, from 2003 to 2008. Under his leadership, CCS Medical's annual sales grew from approximately $60 million to over $500 million. Additionally, he was responsible for acquiring and integrating Becton Dickenson's blood glucose monitoring division into the CCS product line and commercializing it under the Nova Max brand.

Prior to joining CCS, Capper worked with Bayer Healthcare's diabetes care division, where he served as the division's national sales director. He holds a Bachelor of Science in Accounting from West Chester University and an MBA in International Finance from George Washington University.

X
This ad will auto-close in 10 seconds